Ismael Lares-Asseff | Pharmacology | Lifetime achievement Award

Posted on by ScienceFather

Assoc. Prof. Dr. Ismael Lares-Asseff | Pharmacology | Lifetime achievement Award

Assoc. Prof. Dr. Ismael Lares-Asseff, Instituto Politécnico Nacional, CIIDIR Durango, Mexico

Dr. Ismael Lares-Asseff, a prominent Mexican researcher, holds a degree in Medicine from UJED and a specialty in Pediatrics from IMAN and UNAM. He earned his Master’s and Ph.D. in Medical Sciences from UNAM, receiving the prestigious “Gabino Barreda Medal.” Mentored by renowned researcher Dr. Joaquín Cravioto, Dr. Lares founded Latin America’s first Clinical Pharmacokinetics Laboratory in 1982. His work spans pediatric pharmacokinetics, malnutrition, and pharmacogenetics among diverse ethnic groups, and he authored influential books like Clinical Pharmacology in Pediatrics and Pharmacogenomics in Latin America. With 190 publications, 671 citations, and numerous awards, he is a leader in personalized medicine.

 

Publication Profile

Scopus

Orcid

Background and Academic Achievements

Assoc. Prof. Dr. Ismael Lares-Asseff holds a distinguished background in medicine, earning degrees and accolades throughout his extensive career. With an MD from the Universidad Juárez del Estado de Durango (UJED), he specialized in Pediatrics through the Children’s Hospital of IMAN and the National Autonomous University of Mexico (UNAM). His academic journey culminated in a Master’s and Doctorate in Medical Sciences from UNAM, where he was awarded the “Gabino Barreda Medal” for his outstanding academic achievements.

Contributions to Pediatric Research and Clinical Pharmacokinetics

Under the mentorship of Dr. Joaquín Cravitoto, a globally respected figure in pediatric research, Dr. Lares-Asseff developed Mexico’s first Clinical Pharmacokinetics Laboratory in 1982. His early research primarily focused on understanding the impact of malnutrition on pediatric pharmacokinetics, producing findings published in prestigious journals. These works led to his internationally recognized book, Clinical Pharmacology in Pediatrics: Pharmacokinetics and Pharmacogenomics, awarded by the Mexican Academy of Pediatrics.

Conclusion

Assoc. Prof. Dr. Ismael Lares-Asseff is an ideal candidate for the Research for Lifetime Achievement Award. His contributions to pediatric pharmacology, pharmacogenetics, and personalized medicine embody a lifelong commitment to advancing medical science and patient care.

 

Publication Top Notes

  • 🧬 Influence of Age, Gender, and BMI on IV Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery, Rivera-Espinosa, L., Vicencio-Rosas, E., et al., Dose-Response, 2024, 0 citations.
  • 👨‍⚕️ Population Pharmacokinetics and Pharmacodynamics of L-asparaginase and Its Impact on Pancreatitis in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Drug and Chemical Toxicology, 2024, 0 citations.
  • 💉 Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Nutrition and Cancer, 2024, 0 citations.
  • 🧪 Impact of SNPs and Nutrition on Doxorubicin Pharmacokinetics and Cardiotoxicity in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Journal of Oncology Pharmacy Practice, 2023, 3 citations.
  • 🌎 Barriers to Pharmacogenomics in Latin America and the Caribbean: Drug/Gene Pairs, Salas-Hernández, A., Galleguillos, M., et al., Frontiers in Pharmacology, 2023, 9 citations.
  • 📝 Pharmacogenetics and Pharmacogenomics in Latin America: Perspectives, López-Cortés, A., Esperón, P., Lares-Asseff, I., et al., Frontiers in Pharmacology, 2023, 3 citations.
  • 🐾 Silver Nanoparticles in Treating Distemper in Dogs: A Clinical Trial, Gastelum-Leyva, F., Pena-Jasso, A., et al., Viruses, 2022, 2 citations.
  • 🔬 Mitochondrial Dysfunction Caused by Zinc Oxide Nanoparticles, Patrón-Romero, L., et al., Crystals, 2022, 16 citations.
  • 🧬 Effect of Levetiracetam on Placental Transporter Gene Expression in Mice, Blanco-Castañeda, R., et al., Epilepsia, 2022, 0 citations.
  • ❤️ Genetic Polymorphisms and Doxorubicin Cardiotoxicity in Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Pharmacogenetics and Genomics, 2021, 8 citations.

 

 

 

Hua Jin | Pharmacology | Women Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Hua Jin | Pharmacology | Women Researcher Award

Assoc Prof Dr. Hua Jin, Guangdong Medical University, China

Assoc. Prof. Dr. Hua Jin is an Associate Professor at Guangdong Medical University, Dongguan, China, specializing in nanochemistry, bionanomaterials, and drug delivery systems. He holds a PhD from Jinan University, China, and completed postdoctoral fellowships at Northwestern University and the University of Illinois at Chicago. Dr. Jin has published over 50 SCI papers with an H-index of 34, and holds multiple international and Chinese patents. His research primarily focuses on nanoparticle-based therapies for lung injuries and cancer. Notable publications include works in J Tissue Eng and Biomaterials Science.

 

Publication profile

Orcid

Education

Assoc. Prof. Dr. Hua Jin earned his Ph.D. in Nanochemistry and Bionanomaterials from Jinan University, Guangzhou, China, from September 2009 to July 2013, graduating in the top 5% of his class. Prior to that, he completed his M.Eng. in Inorganic Chemistry at the same institution from September 2006 to July 2009, also achieving a top 5% ranking. His strong academic background has laid a solid foundation for his innovative research in the fields of chemistry and nanotechnology. 🌟🔬✨

 

Work Experience

Assoc. Prof. Dr. Hua Jin has been an Associate Professor at the College of Medicine, Guangdong Medical University, since September 2018. He brings a wealth of research experience from his postdoctoral fellowships in the United States. From March 2017 to July 2018, he worked at Northwestern University in the Department of Lung Injury and Vascular Disease. Prior to that, from November 2013 to March 2017, he was a postdoctoral fellow in the Department of Pharmacology at the University of Illinois at Chicago. His diverse background enriches his contributions to medical research and education. 🌟🔬

 

Research Achievements

Assoc. Prof. Dr. Hua Jin has made remarkable contributions to research, publishing 50 papers in prestigious SCI journals, showcasing his expertise in his field. His research has garnered significant recognition, with an impressive H-index of 34, reflecting the impactful nature of his work. Dr. Jin also holds two international patents in Australia and three patents in China, highlighting his innovative contributions to science and technology. His achievements demonstrate a commitment to advancing knowledge and pushing the boundaries of research and development. 🌍📚💡

 

Publication Top Notes  

  • Intratracheal Administration of Stem Cell Membrane-Cloaked Naringin-Loaded Biomimetic Nanoparticles Promotes Resolution of Acute Lung Injury (2024) – [Cited by: 2] 🔬
  • Tumor targeting and penetrating biomimetic mesoporous polydopamine nanoparticles facilitate photothermal killing and autophagy blocking for synergistic tumor ablation (2021) – [Cited by: 15] 📈
  • Berberine-Loaded Biomimetic Nanoparticles Attenuate Inflammation of Experimental Allergic Asthma via Enhancing IL-12 Expression (2021) – [Cited by: 10] 🌱
  • Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway (2021) – [Cited by: 8] 🥇
  • GE11 Peptide Conjugated Liposomes for EGFR-Targeted and Chemophotothermal Combined Anticancer Therapy (2021) – [Cited by: 5] 💊
  • Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury (2021) – [Cited by: 3] 🐭
  • Peptide-Decorated Supramolecules for Subcellular Targeted Cancer Therapy: Recent Advances (2020) – [Cited by: 20] 📚
  • Macrophage‐Targeted Isoniazid–Selenium Nanoparticles Promote Antimicrobial Immunity and Synergize Bactericidal Destruction of Tuberculosis Bacilli (2020) – [Cited by: 12] 🦠
  • Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis (2020) – [Cited by: 18] 🎯
  • EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy (2017) – [Cited by: 6] 🌼

Patricia Rijo |Pharmacology, Toxicology | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Patricia Rijo |Pharmacology, Toxicology | Best Researcher Award

Assoc Prof Dr, Patricia Rijo, Universidade Lusófona, Portugal

Assoc Prof Dr. Patricia Rijo is a distinguished academic at Universidade Lusófona in Portugal. With expertise in [mention her field or area of specialization], Dr. Rijo has contributed significantly to [mention any notable contributions or achievements, such as research, publications, or projects]. Her dedication to [mention any relevant causes or academic interests] underscores her commitment to advancing knowledge in her field. Dr. Rijo’s academic leadership and mentorship inspire both colleagues and students alike at Universidade Lusófona.

Publication profile

Scopus

Education

PhD in Pharmacy (specialty in Medicinal Chemistry and Therapeutics) with Distinction, Faculdade de Farmácia da Universidade de Lisboa, 2003.,Master’s Degree (MSc) in Medicinal Chemistry, Faculdade de Farmácia da Universidade de Lisboa, 2003.,Bachelor’s Degree in Chemistry, Faculdade de Ciências da Universidade de Lisboa, 1999.

Professional Experience

Dr. Hyunsook Lee has had a distinguished professional career in academia and research 👩‍🔬. She began as a Research Scientist at Mogam Biotech Research Institute in Korea (1992. Mar – 1994. May) 🔬 and was promoted to Senior Research Scientist (1994. May – 1996. Aug) 🧬. She then transitioned to academia as a Research Assistant Professor at Ewha Womans University (2002. Sept – 2003) 🧪. In 2004, she joined the Dept. of Biological Sciences at Seoul National University (SNU) as an Assistant Professor 📚, advancing to Associate Professor in 2008 and earning early tenure in 2010 🌟. By 2012, she became a full Professor at SNU 🌍. Dr. Lee has also served in several key administrative roles, including Vice Dean of Planning for the College of Natural Sciences (2015 July – 2017 June) 📅, and Dean for Research Affairs at SNU (2021. Feb – 2023. Feb) 🎓. She has been the Head of the AI-Bio Research Center since 2023 🧠🔬 and co-founded Next & Bio in 2019, which later merged with Kolmar Holdings in 2022 💼. Her visiting scientist positions include stints at the Dana Farber Cancer Institute (2010. Aug – 2011. July) 🧬 and Samsung Advanced Institute of Technology (2020. Aug – 2021. Feb) 🏥.

Academic Positions:

Associate Professor at Universidade Lusófona de Humanidades e Tecnologias (ULHT), since June 2020.,Assistant Professor at ULHT (2011-2020).,Coordinator Professor at Escola Superior de Ciências da Saúde (2011-2016).,Assistant at ULHT (2005-2010).,Invited Assistant Professor at Escola Superior de Saúde Ribeiro Sanches (2002-2011).,Monitor at Faculdade de Farmácia da Universidade de Lisboa (2001-2005).

Awards and Honors:

Egon Stahl-Award in Bronze from Society for Medicinal Plant and Natural Product Research (2022).,Various awards for scientific presentations and research contributions.

Additional Skills and Activities:

  • Languages: Proficiency in Portuguese (C2), English (B2), Spanish (B1), French (A2).
  • Supervision: Supervised numerous PhD and Master’s students.
  • Project Leadership: Participation and leadership in multiple research projects.

Publications:

  • Anticancer diterpenes of African natural products: Mechanistic pathways and preclinical developments
    • Authors: Bangay, G., Brauning, F.Z., Rosatella, A., Efferth, T., Rijo, P.
    • Journal: Phytomedicine, 2024, 129, 155634
    • Abstract: This article likely discusses the mechanistic pathways through which diterpenes from African natural products exhibit anticancer properties, as well as their development in preclinical studies.
  • Glycyrrhizic Acid Nanoparticles Subside the Activity of Methicillin-Resistant Staphylococcus aureus by Suppressing PBP2a
    • Authors: Rijo, P., Abuamara, T.M.M., Ali Lashin, L.S., Abd El Maksoud, A.I., Hassan, A.
    • Journal: Pharmaceuticals, 2024, 17(5), 589
    • Abstract: This article likely explores the use of glycyrrhizic acid nanoparticles to combat methicillin-resistant Staphylococcus aureus (MRSA) by targeting the penicillin-binding protein PBP2a.
  • Halimane Derivatives from Plectranthus ornatus Codd. as Novel Anti-cancer Agents
    • Authors: Bangay, G., Brauning, F.Z., Kowalczyk, T., Sitarek, P., Rijo, P.
    • Journal: Biomedicine and Pharmacotherapy, 2024, 174, 116516
    • Abstract: This article likely investigates the anticancer potential of halimane derivatives from Plectranthus ornatus.
  • Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP
    • Authors: Seguin-Devaux, C., Mestrovic, T., Arts, J.J., Rijo, P., Mori, M.
    • Journal: Drug Resistance Updates, 2024, 74, 101069
    • Abstract: This editorial likely outlines the efforts and strategies of the COST Action CA21145 EURESTOP in addressing antibacterial resistance in Europe.
  • Biological Activity of 6,7-Dehydroxyroyleanone and Derivatives Obtained from Plectranthus aliciae (Codd) A.J.Paton
    • Authors: Filipe, M.S., Domínguez-Martín, E.M., Pires, T.C.S.P., Barros, L., Rijo, P.
    • Journal: ACS Omega, 2024, 9(16), pp. 18113–18118
    • Abstract: This article likely details the biological activities of 6,7-dehydroxyroyleanone and its derivatives sourced from Plectranthus aliciae.
  • Exploring the Anticancer Potential of Semisynthetic Derivatives of 7α-Acetoxy-6β-hydroxyroyleanone from Plectranthus sp.: An In Silico Approach
    • Authors: Merecz-Sadowska, A., Isca, V.M.S., Sitarek, P., Rijo, P., Zajdel, R.
    • Journal: International Journal of Molecular Sciences, 2024, 25(8)
    • Abstract: This article likely explores the anticancer potential of semisynthetic derivatives of a specific compound from Plectranthus species using computational methods.
  • Anticancer Effects of Abietane Diterpene 7α-Acetoxy-6β-hydroxyroyleanone from Plectranthus grandidentatus and Its Semi-Synthetic Analogs: An In Silico Computational Approach
    • Authors: Isca, V.M.S., Sitarek, P., Merecz-Sadowska, A., Rijo, P., Kowalczyk, T.
    • Journal: Molecules, 2024, 29(8), 1807
    • Abstract: This article likely investigates the anticancer effects of abietane diterpene and its analogs from Plectranthus grandidentatus using computational techniques.
  • Antibiotic Coordination Frameworks against Antibiotic Resistance: How to Involve Students through Experimental Practices in the Search for Solutions to Public Health Problems
    • Authors: Domínguez-Martín, E.M., Ntungwe, E., Isca, V.M.S., André, V., Rijo, P.
    • Journal: Journal of Chemical Education, 2024, 101(5), pp. 2045–2051
    • Abstract: This article likely discusses educational strategies to involve students in experimental practices to address antibiotic resistance.
  • The Precious Potential of the Sacred Tree Chamaecyparis obtusa (Siebold & Zucc.) Endl. as a Source of Secondary Metabolites with Broad Biological Applications
    • Authors: Górski, K.M., Kowalczyk, T., Picot, L., Ghorbanpour, M., Sitarek, P.
    • Journal: International Journal of Molecular Sciences, 2024, 25(5), 2723
    • Abstract: This review likely highlights the various biological applications of secondary metabolites derived from Chamaecyparis obtusa.
  • Enhancement of Vitamin C’s Protective Effect against Thimerosal-Induced Neurotoxicity in the Cerebral Cortex of Wistar Albino Rats: An In Vivo and Computational Study
    • Authors: Hassan, A., Mohsen, R., Rezk, A., Abd El Maksoud, A.I., Mohamed, A.F.
    • Journal: ACS Omega, 2024, 9(8), pp. 8973–8984
    • Abstract: This article likely explores the neuroprotective effects of vitamin C against thimerosal-induced toxicity using both in vivo and computational methods.